Beta blocker therapy declined

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and heart failure were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (46.8

Effect: decline; adjusted OR 0.66; CI: 95% CI = 0.55-0.79

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.

Effect: decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73